Search results

Order by most recent / most popular / relevance

Results: 1-10 of 25

Denial of leave to amend securities complaint affirmed on basis of futility

Katten Muchin Rosenman LLP
-
USA
-
March 28 2008

The Court of Appeals for the Eighth Circuit affirmed a decision dismissing Plaintiff’s class action securities fraud complaint and denying Plaintiff leave to amend

Third Circuit vacates dismissal of Celebrex securities fraud class action

Edwards Wildman Palmer LLP
-
USA
-
February 17 2009

The United States Court of Appeals for the Third Circuit (“Third Circuit”) recently vacated the dismissal of a securities fraud class action alleging that a pharmaceutical company, Pharmacia, Inc., made materially false statements about a clinical study of a popular anti-inflammatory medication

United States Supreme Court skeptical of requiring statistical significance as the test to determine materiality in securities fraud cases

Morrison & Foerster LLP
-
USA
-
January 11 2011

On Monday, January 10, 2011, the Supreme Court heard arguments in Matrixx Initiatives, Inc. v. Siracusano, No. 09-1156

French doctor charged in criminal and civil insider trading cases

Porter Wright Morris & Arthur LLP
-
USA
-
November 3 2010

The criminalization of securities enforcement has increased in recent years

U.S. Supreme Court rules that a drug’s adverse event reports may be material to investors even though not "statistically significant"

Jones Day
-
USA
-
March 28 2011

On March 22, 2011, the U.S. Supreme Court issued its long-awaited opinion in Matrixx Initiatives, Inc. v. Siracusano (No. 09-1156

Supreme Court rejects statistical significance as bright-line rule for materiality

Katten Muchin Rosenman LLP
-
USA
-
March 25 2011

The U.S. Supreme Court found that allegations of "statistical significance" were not a requirement for pleading materiality in a securities fraud action arising from a pharmaceutical company's alleged failure to disclose reports linking its cold remedy with loss of smell

SEC brings fraud case against biopharmaceutical company, three other companies and four executives for misleading investors about sole product and insider trading

Porter Wright Morris & Arthur LLP
-
USA
-
August 2 2011

On Monday, August 1, 2011, the SEC filed suit against eight defendants for making false statements in public filings regarding the status of the human clinical trials for the drug SF-1019 by Argyll Biotechnologies LLC

Scienter inadequately pled under the standard set forth in the PSLRA

Katten Muchin Rosenman LLP
-
USA
-
October 8 2010

The U.S. District Court for the Southern District of Indiana dismissed plaintiff’s securities fraud action against a nationwide health care benefits provider, and its officers and directors, in which plaintiff alleged that defendants artificially inflated the price of the stock by making certain false and misleading statements

Matrixx Securities fraud case could affect product liability law

Squire Sanders
-
USA
-
December 10 2010

Sometimes the most significant changes in the law come from unexpected places

Two recent false claims decisions issued by the federal courts

Bricker & Eckler LLP
-
USA
-
May 25 2011

On May 16, 2011, the U.S. Supreme Court ruled that False Claims Act (FCA) cases brought by whistleblowers who base their allegations on information found in records released by federal agencies pursuant to a Freedom of Information Act (FOIA) request are subject to the “public disclosure” bar

next >

Search results

Denial of leave to amend securities complaint affirmed on basis of futility

Third Circuit vacates dismissal of Celebrex securities fraud class action

United States Supreme Court skeptical of requiring statistical significance as the test to determine materiality in securities fraud cases

French doctor charged in criminal and civil insider trading cases

U.S. Supreme Court rules that a drug’s adverse event reports may be material to investors even though not "statistically significant"

Supreme Court rejects statistical significance as bright-line rule for materiality

SEC brings fraud case against biopharmaceutical company, three other companies and four executives for misleading investors about sole product and insider trading

Scienter inadequately pled under the standard set forth in the PSLRA

Matrixx Securities fraud case could affect product liability law

Two recent false claims decisions issued by the federal courts

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea